UCN-01 and Irinotecan in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from
dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor
cells.
PURPOSE: Phase I trial to study the effectiveness of combining UCN-01 with irinotecan in
treating patients who have advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins